Bevacizumab (BEV) plus capecitabine as maintenance therapy after initial treatment with BEV plus XELOX in previously untreated patients (pts) with metastatic colorectal cancer (mCRC): Mature data from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback